Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 11/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | GALK1 | P51570 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160623 | 0.95 | ITGA4 (0.39) | ITGA4ITGB1MEN1ALDH1A1KMT2A | |
| SCHEMBL5162238 | 0.81 | ITGB1 (0.51) | ITGA4ITGB1 | |
| SCHEMBL5163519 | 0.73 | ITGB1 (0.41) | ITGA4ITGB1 | |
| SCHEMBL14371623 | 0.72 | ITGA4 (0.52) | ITGA4ITGB1 | |
| SCHEMBL14608581 | 0.71 | ITGB1 (0.48) | ITGA4ITGB1 | |
| SCHEMBL14371614 | 0.70 | ITGB1 (0.57) | ITGA4ITGB1 | |
| SCHEMBL14608783 | 0.67 | ITGA4 (0.48) | ITGA4ITGB1HCRTR1 | |
| SCHEMBL5158658 | 0.67 | ITGA4 (0.41) | ITGA4ITGB1HCRTR1 | |
| SCHEMBL14371774 | 0.67 | ITGA4 (0.50) | ITGA4ITGB1 | |
| SCHEMBL5175728 | 0.67 | ITGB1 (0.39) | ITGA4ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | ITGA4 3/4885ITGB1 9/4885MEN1 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.